A multicenter study of annual health service utilization and costs in rheumatoid arthritis
- PMID: 3707626
- DOI: 10.1002/art.1780290405
A multicenter study of annual health service utilization and costs in rheumatoid arthritis
Abstract
The economic impact of chronic illness has important implications for medical practice and health policy. To determine the yearly costs of illness for those who have rheumatoid arthritis, a detailed, self-administered questionnaire was developed. The questionnaire was completed by 940 patients. Direct costs (recorded as charges) include the average annual expenditures by all patients and third party payers for: hospital care ($913), physician costs ($206), other health professional visits ($71), medications ($436), laboratory tests ($217), radiographs ($116), assistive devices ($24), and nontraditional therapies ($22). The total annual medical costs per patient were $2,533. In a multivariate analysis that controlled for age, sex, education, and disease duration, the outpatient costs, inpatient costs, and total costs were all positively related to the Health Assessment Questionnaire Disability Index (P f less than 0.01) and global health (P f less than 0.01), but were not associated with self-reported pain.
Similar articles
-
The costs of rheumatoid arthritis.Pharmacoeconomics. 1994 Dec;6(6):513-22. doi: 10.2165/00019053-199406060-00005. Pharmacoeconomics. 1994. PMID: 10155281 Review.
-
[A multicenter cross-sectional study on the health related quality of life of patients with rheumatoid arthritis using a revised Japanese version of the arthritis impact measurement scales version 2 (AIMS 2), focusing on the medical care costs and their associative factors].Ryumachi. 2002 Feb;42(1):23-39. Ryumachi. 2002. PMID: 11925904 Japanese.
-
Radiographic damage in rheumatoid arthritis correlates with functional disability but not direct medical costs.J Rheumatol. 2001 Nov;28(11):2416-24. J Rheumatol. 2001. PMID: 11708412
-
Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis.J Rheumatol. 1999 May;26(5):1068-75. J Rheumatol. 1999. PMID: 10332970
-
Rheumatoid arthritis: direct and indirect costs.Joint Bone Spine. 2004 Nov;71(6):518-24. doi: 10.1016/j.jbspin.2004.01.003. Joint Bone Spine. 2004. PMID: 15589432 Review.
Cited by
-
Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece.Clinicoecon Outcomes Res. 2015 Jan 16;7:85-93. doi: 10.2147/CEOR.S75323. eCollection 2015. Clinicoecon Outcomes Res. 2015. PMID: 25653545 Free PMC article.
-
Epidemiology and burden of illness of rheumatoid arthritis.Pharmacoeconomics. 2004;22(2 Suppl 1):1-12. doi: 10.2165/00019053-200422001-00002. Pharmacoeconomics. 2004. PMID: 15157000 Review.
-
Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs).Pharmacoeconomics. 1993 Feb;3(2):107-23. doi: 10.2165/00019053-199303020-00004. Pharmacoeconomics. 1993. PMID: 10146960 Review.
-
The costs of rheumatoid arthritis.Pharmacoeconomics. 1994 Dec;6(6):513-22. doi: 10.2165/00019053-199406060-00005. Pharmacoeconomics. 1994. PMID: 10155281 Review.
-
Determinants of direct costs in Dutch rheumatoid arthritis patients.Ann Rheum Dis. 2004 Jul;63(7):817-24. doi: 10.1136/ard.2003.014340. Ann Rheum Dis. 2004. PMID: 15194577 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical